fashion -WSS

fashion

author：fashion 2025-09-07 14:01:30 - browse：8725

Treeline Northwest — AP Photo/Ted S. Warren

Josh Bilenker’s last company, Loxo Oncology, was purchased by Eli Lilly for $8 billion. No surprise, then, that his next effort has already raised at least $473 million in funding from private investors even before telling the public what, exactly, it is working on.

Treeline Biosciences, the new venture by Bilenker and Jeffrey Engelman, formerly Novartis’s top cancer researcher, has hired more than 130 people across three research sites in little more than a year, according to a company blog post, regulatory filings, and STAT reporting.

Treeline’s website doesn’t mention a single drug target or disease. In a paper published last year in Nature Cancer, Engelman and several colleagues reviewed the history of a class of cancer drugs called PI3 kinase inhibitors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Drug firms test therapies to halt Alzheimer’s before symptoms arise

focus

WSS

What do new weight loss drugs mean for bariatric surgery?

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

In science, is the line between industry and academia shifting?

NVIDIA and Google execs on the future of AI and drug discovery

As pharma fights Medicare drug negotiation, hospitals, docs silent

Arc Institute generative AI designs new CRISPR systems

hotspot

fashion

leisure time

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

What AAP's gender

How to save PrEP access — and even expand it

Radiation, mainstay of cancer treatment, begins a fade

In age of alternative facts, a scholarly course on calling out crap

Military medical care influenced by rank and race, new study finds

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

As pharma fights Medicare drug negotiation, hospitals, docs silent

Anesthesiologist group: stop taking Ozempic before surgery

Second House panel advances two

knowledge

Australia’s approach to dialysis celebrates life

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

In science, is the line between industry and academia shifting?

AstraZeneca bets AAV gene therapy will still deliver the goods

FDA panel gives mixed vote on blood pressure devices

AstraZeneca challenges Medicare drug negotiation program

focus

Wikipedia

knowledge

hotspot